Citadel Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,200
| Closed | -$47.3K | – | 15884 |
|
|
2024
Q1 | $47.3K | Sell |
3,200
-2,300
| -42% | -$32.3K | ﹤0.01% | 12223 |
|
|
2023
Q4 | $73.8K | Buy |
5,500
+1,600
| +41% | +$20.2K | ﹤0.01% | 11323 |
|
|
2023
Q3 | $48.1K | Sell |
3,900
-1,000
| -20% | -$12.1K | ﹤0.01% | 11800 |
|
|
2023
Q2 | $60.3K | Sell |
4,900
-14,600
| -75% | -$183K | ﹤0.01% | 11586 |
|
|
2023
Q1 | $240K | Sell |
19,500
-10,300
| -35% | -$121K | ﹤0.01% | 9843 |
|
|
2022
Q4 | $342K | Buy |
+29,800
| New | +$245K | ﹤0.01% | 9030 |
|
|
2022
Q2 | – | Sell |
-11,300
| Closed | -$71K | – | 14917 |
|
|
2022
Q1 | $71K | Buy |
+11,300
| New | +$63.5K | ﹤0.01% | 12575 |
|
|
2021
Q3 | – | Sell |
-11,500
| Closed | -$73K | – | 15376 |
|
|
2021
Q2 | $73K | Sell |
11,500
-59,400
| -84% | -$392K | ﹤0.01% | 13141 |
|
|
2021
Q1 | $445K | Buy |
+70,900
| New | +$507K | ﹤0.01% | 9937 |
|
|
2018
Q4 | – | Sell |
-23,386
| Closed | -$98K | – | 10307 |
|
|
2018
Q3 | $98K | Sell |
23,386
-13,854
| -37% | -$58.4K | ﹤0.01% | 8588 |
|
|
2018
Q2 | $144K | Buy |
+37,240
| New | +$247K | ﹤0.01% | 8094 |
|
|
2017
Q3 | – | Sell |
-1,309
| Closed | -$13K | – | 8470 |
|
|
2017
Q2 | $13K | Sell |
1,309
-15,672
| -92% | -$320K | ﹤0.01% | 7360 |
|
|
2017
Q1 | $411K | Buy |
16,981
+12,812
| +307% | +$321K | ﹤0.01% | 5358 |
|
|
2016
Q4 | $134K | Sell |
4,169
-3,254
| -44% | -$139K | ﹤0.01% | 6562 |
|
|
2016
Q3 | $371K | Buy |
7,423
+6,038
| +436% | +$251K | ﹤0.01% | 5332 |
|
|
2016
Q2 | $59K | Buy |
+1,385
| New | +$75.4K | ﹤0.01% | 6371 |
|
|
2016
Q1 | – | Sell |
-1,398
| Closed | -$87K | – | 8796 |
|
|
2015
Q4 | $87K | Sell |
1,398
-2,046
| -59% | -$144K | ﹤0.01% | 6840 |
|
|
2015
Q3 | $231K | Buy |
3,444
+915
| +36% | +$74.7K | ﹤0.01% | 5951 |
|
|
2015
Q2 | $246K | Sell |
2,529
-1,106
| -30% | -$105K | ﹤0.01% | 6037 |
|
|
2015
Q1 | $340K | Buy |
3,635
+1,894
| +109% | +$161K | ﹤0.01% | 5474 |
|
|
2014
Q4 | $155K | Sell |
1,741
-2,720
| -61% | -$198K | ﹤0.01% | 6261 |
|
|
2014
Q3 | $308K | Buy |
4,461
+3,444
| +339% | +$184K | ﹤0.01% | 5239 |
|
|
2014
Q2 | $58K | Sell |
1,017
-1,627
| -62% | -$82.6K | ﹤0.01% | 6658 |
|
|
2014
Q1 | $105K | Buy |
2,644
+1,411
| +114% | +$60.4K | ﹤0.01% | 6155 |
|
|
2013
Q4 | $52K | Buy |
1,233
+928
| +304% | +$26.9K | ﹤0.01% | 6018 |
|
|
2013
Q3 | $9K | Buy |
+305
| New | +$10.7K | ﹤0.01% | 6501 |
|
Other funds holding MACK
RA
JC
Citadel Advisors's MACK Position: Q2 2024 in Review
Citadel Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 444 shares — an estimated $6.56K sold.
Citadel Advisors first reported a position in MACK in Q3 2013 and held it in 30 quarters. The position peaked at $5.32M in Q3 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Citadel Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Citadel Advisors sold 444 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $6.56K.
- Citadel Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 30 quarters.
- Citadel Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $5.32M in Q3 2015.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.